Amgen Seeks Retrial in $50.3 Million Patent Dispute with Lindis Biotech Over Leukemia Treatment

Amgen, the American biopharmaceutical giant, is seeking a new trial in a Delaware federal court following a verdict that requires it to pay $50.3 million to Germany’s Lindis Biotech GmbH. The jury found Amgen liable for encouraging healthcare providers to infringe upon Lindis Biotech’s immunotherapy patents concerning a leukemia treatment. The contentious issue stems from the administration of this treatment, which Lindis claims violated their intellectual property rights. Amgen’s request for a retrial underscores the ongoing legal battles in the pharmaceutical sector over patent infringements. For more details, visit the original article.